Title of Study: A Study of P38 Inhibitor (4) Monotherapy in Patients with Active Rheumatoid Arthritis
Fast Facts:
Protocol number:
PA18604
Sponsor:
Hoffmann-La Roche
Company division:
Pharmaceutical
Product name:
P38 Inhibitor (4)
Phase of development:
II
Therapeutic area, approved indication:
Rheumatoid Arthritis
Date of report:
5/2/2008
Clinical study summary: No data will be posted since Roche made a strategic decision to terminate the project. The decision was based on failure to achieve the pre-specified efficacy endpoints of the study, and was not due to an unacceptable safety profile.
This site is run by CenterWatch, a publishing company that focuses on the clinical Trial Listings industry. The information provided in this service is designed to help patients find clinical Trial Results that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these Trial Listings.
Trial Results updated:
August 29, 2008 at 10:30:01 AM
